Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indo-Turkish Biosimilar Connections Build

Executive Summary

More Indian firms appear keen to target the Turkish market for biosimilars. After Dr Reddy's outlined its plans earlier this year, Zydus Cadila has now firmed up an alliance with Turkey's Eczacibasi Ilac Pazarlama AS for biosimilars especially in the oncology segment.

You may also be interested in...



Eczacibasi Capintec Divestment Talks Signal Pharma Refocus?

Eczacibasi is in talks to sell its US-based nuclear medicine operation Capintec, in a move that appears to signal an intention by the Turkish healthcare group to focus again on the mainstream pharma sector.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.

Zydus' Humira Biosimilar: The Story So Far In India

One dose of AbbVie's blockbuster biologic, Humira (adalimumab), in the US equals around six doses of Zydus Cadila's cut-price biosimilar version in terms of the cost of therapy and the Indian firm's product appears to have triggered interesting shifts both in treatment dynamics and the competitive landscape on the domestic market.

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel